背景:电子烟(EC)或电子烟产品的广泛使用导致呼吸系统疾病,包括2019年在全国范围内爆发电子烟或电子烟产品使用相关肺损伤(EVALI)。现在也报告了慢性不良健康影响。为了解决这个重要的公共卫生问题,需要一种创新的流行病控制和流行病学研究方法。我们旨在使用智能手机应用程序数据评估短期和长期使用EC产品与成人呼吸健康之间的关联。
方法:以人口为基础,重复的措施,纵向智能手机应用研究在2020年8月至2021年3月期间对每位参与者进行了为期8天的60天调查参与,其中包括306名美国21岁及以上的参与者.参与者被要求每天填写呼吸健康问卷,每周,每月在他们的智能手机应用程序上。我们使用广义线性混合模型(GLMMs)分析了吸烟习惯与呼吸健康之间的关联。
结果:前7天使用EC与频繁咳嗽有关(OR:5.15,95%CI:2.18,12.21),慢性咳嗽(OR:3.92,95%CI:1.62,9.45),痰多(OR:3.99,95%CI:1.44,11.10),慢性痰(OR:3.55,95%CI:1.41,8.96),咳嗽和痰的发作(OR:4.68,95%CI:1.94,11.28),mMRC3-4级呼吸困难(OR:3.32,95%CI:1.35至8.13),胸寒(OR:3.07,95%CI:1.29,7.33),眼刺激(OR:2.94,95%CI:1.34,6.47)和鼻刺激(OR:2.02,95%CI:0.95,4.30)。过去90天使用EC的相对长期影响与喘息风险增加相关(OR:3.04,95%CI:1.31,7.03),喘息发作(OR:2.78,95%CI:1.07,7.24),mMRC3-4级呼吸困难(OR:2.54,9%CI:1.05至6.18),眼睛刺激(OR:3.16,95%CI:1.49,6.68),和过去一个月的眼睛刺激(OR:3.50,95%CI:1.52,8.04)。
结论:在这项基于智能手机应用程序的重复测量研究中,短期和相对长期使用EC会增加呼吸道症状的风险.
BACKGROUND: Widespread use of e-cigarette (EC) or vaping products causes respiratory disorders including the nationwide outbreak of e-cigarette or vaping product use-associated lung injury (EVALI) in 2019. Chronic adverse health effects are now being reported as well. To address this important public health issue, an innovative approach of epidemic control and epidemiologic study is required. We aimed to assess the association between short-term and long-term use of EC products and respiratory health in adults using smartphone app data.
METHODS: A population-based, repeated measures, longitudinal smartphone app study that performed 8-day survey participation over 60 days for each participant from August 2020 to March 2021, including 306 participants aged 21 years and older in the US. The participants were asked to complete the respiratory health questionnaire daily, weekly, and monthly on their smartphone app. We analyzed the association between vaping habits and respiratory health using generalized linear mixed models (GLMMs).
RESULTS: EC use in the previous 7 days was associated with frequent cough (OR: 5.15, 95% CI: 2.18, 12.21), chronic cough (OR: 3.92, 95% CI: 1.62, 9.45), frequent phlegm (OR: 3.99, 95% CI: 1.44, 11.10), chronic phlegm (OR: 3.55, 95% CI: 1.41, 8.96), episodes of cough and phlegm (OR: 4.68, 95% CI: 1.94, 11.28), mMRC grade 3-4 dyspnea (OR: 3.32, 95% CI: 1.35 to 8.13), chest cold (OR: 3.07, 95% CI: 1.29, 7.33), eye irritation (OR: 2.94, 95% CI: 1.34, 6.47) and nose irritation (OR : 2.02, 95% CI: 0.95, 4.30). Relatively long-term effects of the past 90 days EC use was associated with an increased risk of wheeze (OR: 3.04, 95% CI: 1.31, 7.03), wheeze attack (OR: 2.78, 95% CI: 1.07, 7.24), mMRC grade 3-4 dyspnea (OR: 2.54, 9% CI: 1.05 to 6.18), eye irritation (OR: 3.16, 95% CI: 1.49, 6.68), and eye irritation during the past month (OR: 3.50, 95% CI: 1.52, 8.04).
CONCLUSIONS: In this smartphone app-based repeated measures study, short-term and relatively long-term use of EC increased the risk of respiratory symptoms.